Keisuke Kataoka Laboratory(片岡 圭亮 研究室)
@kataoka_lab
Division of Molecular Oncology, National Cancer Center Research Institute. 国立がん研究センター研究所 分子腫瘍学分野
【Paper Published】Our new paper from @kataoka_lab by Kentaro Yamaguchi, @JunjiKoya, and Kota Mizuno et al. has been published in @BloodAdvances. We performed in vivo CRISPR loss-of-function screening targeting 86 genes recurrently altered in DLBCL. (ashpublications.org/bloodadvances/…)
*New Open-Access Long Read Resource*. We sequenced 1,019 genomes from the 1000 Genomes Project sample cohort using @nanopore. Sequencing data is available at bit.ly/4m8dlE2. @embl @HHU_de @IMPvienna @CRGenomica nature.com/articles/s4158… [1/8]
I am very excited to share our publication, out now in Nature, detailing our developed CRAFTseq methodology for capturing and analysing single cell genomic DNA amplicons alongside the transcriptome and cell surface protein expression. nature.com/articles/s4158…
✍️ Writing is thinking. 👉🏼A powerful editorial in Nature Reviews Bioengineering (Vol. 3, p. 431, 2025) reminds us of something timeless: in science, writing is far more than reporting results. It’s a way of sharpening thought. 👉🏼Even in an age shaped by large-language models,…
日本血液学会の公式Xです。医療・学会関連の情報を中心に、学会活動の現況、業務の合間の雑感など日々の気づきなども発信していければと思っております。どうぞよろしくお願いいたします。
第16回JSH国際シンポジウム(鎌倉)のHPがオープンしました!演題募集・プログラム等、詳細については、随時ご案内していきます。 【会 期】2026年5月15日(金)~16日(土) 【会 場】鎌倉プリンスホテル 【会 長】中島 秀明(横浜市立大学大学院医学研究科) jshem.or.jp/jshis/2026/
第87回日本血液学会学術集会開催のご案内 7月下旬から宿泊予約開始します。 【会期】2025年10月10日(金)~12日(日) 【会場】神戸国際会議場・神戸国際展示場・神戸ポートピアホテル 【会長】清井 仁(名古屋大学大学院医学系研究科 血液・腫瘍内科学) jshem.or.jp/87/
🚨 New paper in @NatureGenet ! How does cancer chemotherapy reshape the HSC landscape and drive the evolution of therapy-related myeloid neoplasms? We uncovered this process through single-colony WGS! See the full paper here! nature.com/articles/s4158…
⭐️Tumor-agnostic precision oncology: finding vs threading the needle. This figure illustrates the dual challenges in tumor-agnostic precision oncology. On one hand, we have achieved significant advances in identifying actionable alterations across various cancer types, akin to…
Original Article: Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma (MIDAS phase 3 trial) nej.md/4mkaecR #ASCO25 | @ASCO
【論文発表】 onlinelibrary.wiley.com/doi/10.1002/aj…
CD19-specific CAR T cells engineered to secrete interleukin-18 were used to treat patients with lymphoma after previous CAR T failure, with a complete or partial response of 81% and a complete response of 52%. Full trial results: nej.md/4jSiXkX
Happy to share our latest paper from@LeukemiaJnl. Ito and colleagues reveal the genetic landscape of nTFHL evaluating 173 patients in collaboration with Dr. Masao Nakagawa (Hokkaido Univ.) and Prof. Hiroaki Miyoshi and Prof. Koichi Oshima (Kurume Univ.). nature.com/articles/s4137…
【論文発表】分子腫瘍学分野@kataoka_labの伊藤勇太らによる論文がLeukemia @LeukemiaJnlに掲載されました。北海道大学(中川雅夫)、久留米大学(三好寛明、大島孝一)と共同で、173例の節性T濾胞ヘルパー細胞リンパ腫(nTFHL)を解析し、遺伝子異常の全体像を解明しました。nature.com/articles/s4137…
Excited to share our paper out today in @CellPressNews discovering RNA mis-splicing derived neoantigens & their cognate T cell receptors (TCRs) as well as characterization of endogenous neoantigen T cells in leukemia patients. authors.elsevier.com/sd/article/S00…
Excited to share our latest issue on human hepatocyte organoids! By utilizing human primary hepatocytes, we successfully developed organoids that can stably proliferate for over three months and reproduce a wide range of liver cell functions through differentiation induction.
Nature research paper: Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia go.nature.com/4cwdrBS